licensing einstein technology

Edward Burns, M.D., executive dean, presents opening remarks at "Licensing Einstein Technology: The Inside Story: Metastatic Melanoma & Pain Therapeutics." Presenters and panelists describe the path of a novel melanoma technology invented at Einstein — from its beginnings in the lab to its current stage in clinical trials sponsored by Pain Therapeutics, Inc. (September 24, 2009)

Ekaterina Dadachova, Ph.D., the Sylvia & Robert S. Olnick Faculty Scholar in Cancer Research, discusses the technology she invented with Arturo Casadevall, M.D., Ph.D., and Joshua Nosanchuk, M.D. The technology, radioimmunotherapy of metastatic melanoma with radiolabeled melanin-binding antibodies, was invented at Einstein and is now in clinical trials sponsored by Pain Therapeutics. (September 24, 2009)

Panelists discuss an Einstein innovation moving from "bench to bedside." Einstein-invented technology intended to treat metastatic melanoma is in clinical trials by Pain Therapeutics, Inc. Panelists include: Ekaterina Dadachova, Ph.D., the Sylvia & Robert S. Olnick Faculty Scholar in Cancer Research; John Harb, director of the office of biotechnology; and Remi Barbier,CEO of Pain Therapeutics, Inc. (September 24, 2009)